| Literature DB >> 30965350 |
Weihao Chen1, Xudong Chen1, Yurong Wang1, Tianhao Liu1, Yudan Liang1,2, Ya Xiao1, Liguo Chen1.
Abstract
BACKGROUND More and more recent studies have clearly shown that long non-coding RNA (lncRNA) should be considered as a fundamental part of the ceRNA network, mainly because lncRNA can act as miRNA sponges to regulate the protein-coding gene expression. Nevertheless, it is still not clear how lncRNA-mediated ceRNAs function in cervical squamous cell carcinoma (CESC). Moreover, information about the ceRNA regulatory mechanism is also remarkably limited; thus, prediction of CESC prognosis using ceRNA-related information remains challenging. MATERIAL AND METHODS We collected 306 RNA (lncRNA, miRNA, and mRNA) expression profile datasets obtained from cervical squamous cancer tissues plus 3 more from adjacent cervical tissues via the TCGA database. Subsequently, we constructed a lncRNAs-miRNAs-mRNAs CESC ceRNA network, and Gene Ontology (GO) analysis was carried out. RESULTS We identified a total of 30 DElncRNAs, 70 DEmiRNAs, and 1089 DEmRNAs in CESC. Subsequently, to reveal the expression patterns of dysregulated genes, weighted gene co-expression network analysis was carried out, resulting in 3 co-expression modules with significantly related clinical properties. The constructed aberrant lncRNAs-miRNAs-mRNAs CESC ceRNA network was composed of 17 DEmiRNAs, 5 DElncRNAs, and 7 DEmRNAs. Moreover, the survival analysis was performed for DElncRNAs, DEmiRNAs, and DEmRNAs. CONCLUSIONS The present study shows the involvement of the lncRNA-related ceRNA network in the pathogenesis of CESC. We believe the newly generated ceRNA network will provide more insights into the lncRNA-mediated ceRNA regulatory mechanisms.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30965350 PMCID: PMC6474298 DOI: 10.12659/MSM.913471
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Workflow of the data preparation and analysis.
The top 10 DElncRNAs, DEmiRNAs, and DEmRNAs.
| Gene symbol | |log2FC| | P value | FDR | Dysregulated stage |
|---|---|---|---|---|
| Top 10 DElncRNA | ||||
| PGM5-AS1 | 8.6326 | 2.41E-93 | 2.28E-90 | Down |
| EMX2OS | 4.25477 | 1.05E-09 | 1.25E-07 | Down |
| MIR100HG | 3.42444 | 2.24E-10 | 3.55E-08 | Down |
| AC093010.3 | 3.11185 | 1.57E-19 | 7.47E-17 | Down |
| LINC01139 | 2.68524 | 0.00067 | 0.015134 | Down |
| MIR205HG | 6.509706 | 0.001037 | 0.020499 | Up |
| AL049555.1 | 5.540556 | 3.75E-05 | 0.001482 | Up |
| AL354766.2 | 5.362799 | 0.002883 | 0.0456 | Up |
| MIR9-3HG | 5.004024 | 0.000879 | 0.017754 | Up |
| U62317.2 | 4.734125 | 0.002055 | 0.034215 | Up |
| Top 10 DEmiRNA | ||||
| hsa-mir-133a-2 | 4.50689 | 2.19E-21 | 2.87E-19 | Down |
| hsa-mir-133a-1 | 4.49975 | 3.40E-22 | 5.57E-20 | Down |
| hsa-mir-145 | 4.28937 | 3.90E-32 | 1.28E-29 | Down |
| hsa-mir-1-1 | 4.11872 | 9.70E-17 | 1.06E-14 | Down |
| hsa-mir-1-2 | 4.10623 | 1.87E-16 | 1.76E-14 | Down |
| hsa-mir-944 | 8.032189 | 0.000672 | 0.005372 | Up |
| hsa-mir-205 | 7.807328 | 1.69E-05 | 0.000231 | Up |
| hsa-mir-203a | 5.991917 | 0.000272 | 0.002586 | Up |
| hsa-mir-31 | 5.640633 | 9.80E-05 | 0.001071 | Up |
| hsa-mir-96 | 5.595909 | 1.07E-07 | 3.19E-06 | Up |
| Top 10 DEmRNA | ||||
| DES | 7.61144 | 3.51E-56 | 3.16E-53 | Down |
| CNN1 | 7.54789 | 2.85E-77 | 1.19E-73 | Down |
| ACTG2 | 7.37523 | 2.16E-54 | 1.60E-51 | Down |
| PI16 | 6.9519 | 1.09E-34 | 3.05E-32 | Down |
| MYH11 | 6.9064 | 6.97E-55 | 5.48E-52 | Down |
| CALML3 | 8.505356 | 0.006408 | 0.040904 | Up |
| PITX1 | 7.588409 | 3.30E-06 | 6.28E-05 | Up |
| KRT15 | 7.476535 | 0.005863 | 0.038285 | Up |
| KRT6A | 7.469412 | 0.002422 | 0.019027 | Up |
| KRT5 | 7.393729 | 0.001477 | 0.012715 | Up |
Figure 2Weighted gene co-expression network construction.
Figure 3Module analysis of PPI network. (A) Turquoise hub module. (B) Blue hub module. (C) Brown hub module.
Figure 4Gene Ontology and KEGG pathway analysis.
Clinical and pathological information of CESC patients.
| Clinical feature | Variable | Patients (%) |
|---|---|---|
| Age at diagnosis (years) | >60 | 59 (19.4) |
| ≤60 | 245 (80.6) | |
| Race | White | 209 (68.8) |
| Black or African American | 30 (9.87) | |
| Native Hawaiian or other Pacific islander | 2 (0.61) | |
| Asian | 20 (6.58) | |
| American Indian or Alaska native | 7 (2.3) | |
| Other | 36 (11.84) | |
| Clinical stage | Stage I | 162 (53.29) |
| Stage II | 69 (22.7) | |
| Stage III | 45 (14.8) | |
| Stage IV | 21 (6.91) | |
| Other | 7 (2.3) | |
| Neoplasm histologic grade | g1 | 18 (5.92) |
| g2 | 135 (44.41) | |
| g3 | 118 (38.82) | |
| g4 | 1 (0.33) | |
| gx | 24 (7.89) | |
| Other | 8 (2.63) | |
| HPV status | Indeterminate | 1 (0.33) |
| Negative | 22 (7.24) | |
| Positive | 281 (92.43) | |
| Menopause status | Pre (<6 months since lmp and no prior bilateral ovariectomy and not on estrogen replacement) | 124 (40.79) |
| Post (prior bilateral ovariectomy or >12 mo since lmp with no prior hysterectomy) | 82 (26.97) | |
| Peri (6–12 months since last menstrual period) | 25 (8.22) | |
| Indeterminate (neither pre or postmenopausal) | 3 (0.99) | |
| Other | 70 (23.03) | |
| Lymphovascular involvement | Absent | 71 (23.36) |
| Present | 79 (25.99) | |
| Other | 154 (50.65) | |
| Pathology T stage | T1 | 140 (46.05) |
| T2 | 71 (23.36) | |
| T3 | 20 (6.58) | |
| T4 | 10 (3.29) | |
| Tis | 1 (0.33) | |
| Tx | 17 (5.59) | |
| Other | 45 (14.8) | |
| Pathology N stage | N0 | 133 (43.75) |
| N1 | 60 (19.74) | |
| Nx | 66 (21.71) | |
| Other | 45 (14.8) | |
| Pathology M stage | M0 | 116 (38.16) |
| M1 | 10 (3.29) | |
| Mx | 128 (42.1) | |
| Other | 50 (16.45) |
Figure 5Module-trait relationships.
Figure 6The dysregulated lncRNA-mRNA-miRNA ceRNA network. Rounds denotes lncRNA, and inverted triangles represents miRNA and diamonds represents mRNA. All shapes in red and green stand for up-regulation and down-regulation, respectively.
All node information of ceRNA network.
| Nodes | |log2FC| | FDR | Dysregulated stage |
|---|---|---|---|
| Hub lncRNAs | |||
| MIR205HG | 6.509705742 | 0.020499198 | Up |
| EMX2OS | 4.254768887 | 1.25034E-07 | Down |
| CRNDE | 2.557103416 | 0.014930541 | Up |
| EPB41L4A-AS1 | 2.414220907 | 6.16839E-12 | Down |
| AC132872.1 | 2.191392699 | 5.06E-12 | Down |
| Hub miRNAs | |||
| hsa-mir-205 | 7.807328074 | 0.000231499 | Up |
| hsa-mir-31 | 5.6406334 | 0.001071158 | Up |
| hsa-mir-183 | 5.533759671 | 0.0000159 | Up |
| hsa-mir-141 | 5.082110951 | 0.000000023 | Up |
| hsa-mir-210 | 4.930713592 | 0.000333648 | Up |
| hsa-mir-182 | 4.515097043 | 0.0000834 | Up |
| hsa-mir-145 | 4.28937124 | 1.28E-29 | Down |
| hsa-mir-429 | 4.147416534 | 0.000191854 | Up |
| hsa-mir-204 | 4.077599564 | 0.00000123 | Down |
| hsa-mir-200a | 3.994337067 | 0.000091 | Up |
| hsa-mir-383 | 3.747450302 | 0.004375965 | Down |
| hsa-mir-106a | 3.616312461 | 0.008870532 | Up |
| hsa-mir-100 | 3.219979103 | 4.12E-09 | Down |
| hsa-mir-143 | 3.20692291 | 6.1E-13 | Down |
| hsa-mir-140 | 2.778828132 | 1.68E-23 | Down |
| hsa-mir-32 | 2.246555022 | 0.000218652 | Up |
| hsa-mir-195 | 2.151037526 | 0.0000451 | Down |
| Hub mRNAs | |||
| HCAR2 | 4.881356753 | 0.043430907 | Up |
| FGFR3 | 4.159902463 | 0.026845557 | Up |
| CCNB1 | 4.009891379 | 3.62E-10 | Up |
| E2F1 | 4.006738743 | 0.00000522 | Up |
| KLF5 | 3.575849722 | 0.0000849 | Up |
| PMAIP1 | 3.520103023 | 0.002564182 | Up |
| ITGA2 | 2.965511951 | 0.037274851 | Up |
Figure 7Kaplan-Meier survival curves of ceRNA network for the overall survival in CESC.